Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 12, 2026
- Generate Biomedicines reported a $87.7 million net loss and $404.2 million in cash, cash equivalents, and marketable securities as of Sept. 30, 2026; it believes resources including $30.0 million from Zealand will fund its current operating plan into the first half of 2028.
- 10-Q report · filed Nov 12, 2026
- Generate Biomedicines reported a $216.6 million net loss and $204.4 million in research and development expenses for the nine months ended September 30, 2026; cash, cash equivalents and marketable securities totaled $404.2 million as of September 30, 2026.
The audio replay and transcript follow the call.